| Literature DB >> 35371319 |
Yang Hong1, Jiahui Si1, Bufan Xiao1, Ying Xiong1, Chenyue Dai1, Yue Yang1, Shaolei Li1, Yuanyuan Ma1.
Abstract
Purpose: Due to the high metastatic ability and poor prognosis of lung adenocarcinoma (LUAD), we identified novel non-coding RNAs, which constitute approximately 60% of human transcripts, as prognostic biomarkers and potential therapeutic targets for LUAD.Entities:
Keywords: Hsa-miR-421; Hsa_circ_0000567; LUAD; TMEM100; prognosis
Year: 2022 PMID: 35371319 PMCID: PMC8965118 DOI: 10.7150/jca.60124
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
MicroRNAs related to overall survival ranked by hazard ratio
| No. | Name | EXP (coef) | P | Mean expression | No. | Name | EXP (coef) | P | Mean expression |
|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-mir-1292 | 1.6323 | 0.0096 | 0.5301 | 32 | hsa-mir-450b | 1.0104 | 0.0260 | 19.0439 |
| 2 | hsa-mir-1254 | 1.2914 | 0.0198 | 0.9335 | 33 | hsa-mir-449b | 1.0079 | 0.0454 | 2.7930 |
| 3 | hsa-mir-3940 | 1.2859 | 0.0341 | 1.0549 | 34 | hsa-mir-330 | 1.0075 | 0.0257 | 48.1913 |
| 4 | hsa-mir-3682 | 1.2591 | 0.0068 | 1.1837 | 35 | hsa-mir-31 | 1.0052 | 0.0000 | 22.9920 |
| 5 | hsa-mir-3691 | 1.2471 | 0.0303 | 0.7416 | 36 | hsa-mir-128-2 | 1.0039 | 0.0485 | 73.5355 |
| 6 | hsa-mir-320d-1 | 1.2352 | 0.0493 | 0.5504 | 37 | hsa-mir-222 | 1.0038 | 0.0112 | 83.3141 |
| 7 | hsa-mir-1262 | 1.1545 | 0.0038 | 1.2262 | 38 | hsa-mir-589 | 1.0034 | 0.0094 | 109.7946 |
| 8 | hsa-mir-873 | 1.1318 | 0.0000 | 0.6873 | 39 | hsa-mir-1912 | 1.0029 | 0.0292 | 3.3274 |
| 9 | hsa-mir-7-2 | 1.1203 | 0.0020 | 1.0004 | 40 | hsa-mir-193b | 1.0028 | 0.0334 | 78.3203 |
| 10 | hsa-mir-7-3 | 1.1067 | 0.0082 | 0.9771 | 41 | hsa-mir-424 | 1.0025 | 0.0002 | 89.8590 |
| 11 | hsa-mir-550a-2 | 1.0938 | 0.0006 | 3.3696 | 42 | hsa-mir-193a | 1.0021 | 0.0289 | 210.0761 |
| 12 | hsa-mir-550a-1 | 1.0819 | 0.0008 | 4.1603 | 43 | hsa-mir-584 | 1.0020 | 0.0425 | 40.7900 |
| 13 | hsa-mir-1293 | 1.0554 | 0.0386 | 0.9611 | 44 | hsa-mir-1298 | 1.0010 | 0.0297 | 9.4789 |
| 14 | hsa-mir-450a-2 | 1.0470 | 0.0067 | 4.6204 | 45 | hsa-mir-542 | 1.0009 | 0.0139 | 293.2192 |
| 15 | hsa-mir-147b | 1.0440 | 0.0127 | 3.1276 | 46 | hsa-mir-1911 | 1.0005 | 0.0301 | 21.6588 |
| 16 | hsa-mir-421 | 1.0430 | 0.0016 | 4.7425 | 47 | hsa-mir-582 | 1.0004 | 0.0001 | 412.0279 |
| 17 | hsa-mir-760 | 1.0425 | 0.0001 | 3.2995 | 48 | hsa-mir-27a | 1.0004 | 0.0069 | 1517.0722 |
| 18 | hsa-mir-450a-1 | 1.0390 | 0.0340 | 4.6926 | 49 | hsa-mir-24-2 | 1.0003 | 0.0142 | 2119.4670 |
| 19 | hsa-mir-3677 | 1.0335 | 0.0065 | 7.3630 | 50 | hsa-mir-192 | 1.0000 | 0.0290 | 2348.2164 |
| 20 | hsa-mir-212 | 1.0292 | 0.0484 | 9.8931 | 51 | hsa-mir-10b | 1.0000 | 0.0002 | 7288.5585 |
| 21 | hsa-mir-95 | 1.0282 | 0.0062 | 4.4191 | 52 | hsa-mir-100 | 1.0000 | 0.0233 | 8905.1132 |
| 22 | hsa-mir-138-1 | 1.0253 | 0.0496 | 3.3045 | 53 | hsa-mir-30a | 1.0000 | 0.0235 | 18419.6048 |
| 23 | hsa-mir-935 | 1.0223 | 0.0001 | 3.3771 | 54 | hsa-mir-338 | 0.9995 | 0.0270 | 769.6756 |
| 24 | hsa-mir-412 | 1.0165 | 0.0467 | 4.0426 | 55 | hsa-mir-30c-2 | 0.9990 | 0.0430 | 458.2823 |
| 25 | hsa-mir-365-2 | 1.0151 | 0.0070 | 19.6787 | 56 | hsa-mir-3065 | 0.9976 | 0.0245 | 178.0391 |
| 26 | hsa-mir-769 | 1.0146 | 0.0413 | 23.4524 | 57 | hsa-mir-181c | 0.9944 | 0.0170 | 116.9814 |
| 27 | hsa-mir-365-1 | 1.0131 | 0.0153 | 20.0419 | 58 | hsa-mir-660 | 0.9906 | 0.0407 | 47.8742 |
| 28 | hsa-mir-340 | 1.0124 | 0.0364 | 29.2571 | 59 | hsa-mir-1287 | 0.9905 | 0.0049 | 64.1908 |
| 29 | hsa-mir-7-1 | 1.0111 | 0.0220 | 23.9518 | 60 | hsa-mir-1468 | 0.8968 | 0.0340 | 4.2465 |
| 30 | hsa-mir-505 | 1.0111 | 0.0055 | 41.9137 | 61 | hsa-mir-3189 | 0.7249 | 0.0317 | 1.0393 |
| 31 | hsa-mir-33a | 1.0105 | 0.0025 | 22.4100 |
Correlations between miR-421 expression and clinical characteristics in lung adenocarcinoma patients (n=73)
| Variable | No. of cases | miR-421 expression | P | |
|---|---|---|---|---|
| low | high | |||
| Total | 73 | 37 | 36 | |
| Age (years) | ||||
| ≤60 | 44 | 23 | 21 | 0.7382 |
| >60 | 29 | 14 | 15 | |
| Sex | ||||
| Male | 36 | 14 | 22 |
|
| Female | 37 | 23 | 14 | |
| Smoking | ||||
| No | 43 | 26 | 17 |
|
| Yes | 30 | 11 | 19 | |
| TNM stage | ||||
| I/II | 53 | 29 | 24 | 0.2620 |
| III | 20 | 8 | 12 | |
| Differentiation | ||||
| Poor/moderate | 67 | 31 | 36 |
|
| Good | 6 | 6 | 0 | |
| 5-year survival | ||||
| No | 26 | 8 | 18 |
|
| Yes | 47 | 29 | 18 | |
Multivariate overall survival analysis of prognostic factors for lung adenocarcinoma patients (n=73)
| Variable | Overall survival | ||
|---|---|---|---|
| HR | 95% CI | P | |
| Age (≤60 vs. >60 years) | - | - | 0.140 |
| Sex (male vs. female) | - | - | 0.086 |
| Smoking (no vs. yes) | - | - | 0.928 |
| Pathological stage (I/II vs. III) | - | - | 0.090 |
| Differentiation (poor/moderate vs. good) | - | - | 0.714 |
| miR-421 expression (low vs. high) | 2.593 | 1.127-5.966 | 0.025 |
CI, confidence interval; HR, hazard ratio